These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]
26. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary]. Mezei Z; Bereczki D; Csiba L; Csépány T Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882 [TBL] [Abstract][Full Text] [Related]
27. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T; Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769 [TBL] [Abstract][Full Text] [Related]
28. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Flechter S; Vardi J; Finkelstein Y; Pollak L Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394 [TBL] [Abstract][Full Text] [Related]
29. Assessing disability progression with the Multiple Sclerosis Functional Composite. Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023 [TBL] [Abstract][Full Text] [Related]
30. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466 [TBL] [Abstract][Full Text] [Related]
31. New natural history of interferon-beta-treated relapsing multiple sclerosis. Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502 [TBL] [Abstract][Full Text] [Related]
32. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504 [TBL] [Abstract][Full Text] [Related]
33. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G; Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262 [TBL] [Abstract][Full Text] [Related]
34. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L; N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954 [TBL] [Abstract][Full Text] [Related]
35. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705 [TBL] [Abstract][Full Text] [Related]
36. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960 [TBL] [Abstract][Full Text] [Related]
37. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z; Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282 [TBL] [Abstract][Full Text] [Related]